The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...